Resources Repository
-
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Priority Setting/Ethics | Mental Health | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Global -
ReviewPublication 2016Review: CEA for Maternal, Newborn, Child Health
This chapter summarizes the findings of a systematic search of the cost-effectiveness literature on interventions …
This chapter summarizes the findings of a systematic search of the cost-effectiveness literature on interventions to improve reproductive, maternal, newborn, and child health. Interventions for newborn health, treatment of febrile illness, immunization against preventable diseases, and micronutrient interventions remain among the most cost-effective and affordable. Other studies explore how to provide existing interventions using new platforms to increase outreach or decrease cost per person covered, or both. Interventions provided in the community may achieve both purposes to…
Priority Setting/Ethics | Maternal/Reproductive Health | Costing Methods | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Health Systems | Education/Labor | Health/Medicine | Global -
ArticlePublication 2015Health Gains & Financial Risk Protection by Public Financing in Ethiopia: An ECEA
This article, published in the Lancet Global Health, aims to evaluate the health and financial …
This article, published in the Lancet Global Health, aims to evaluate the health and financial risk protection benefits of selected interventions that could be publicly financed by the government of Ethiopia. The authors used an extended cost-effectiveness analysis (ECEA) to assess the health gains (deaths averted) and financial risk protection afforded (cases of poverty averted) by a bundle of nine interventions that the Government of Ethiopia aims to make universally available. This approach incorporates financial…
Priority Setting/Ethics | Maternal/Reproductive Health | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Health/Medicine | Sub-Saharan Africa -
Lesson/ModulePublication, Teaching Resource 2015CDC Science Ambassador Workshop 2015 Lesson Plan: Seasonal Flu Costs How Much?!
This lesson plan from the Centers for Disease Control and Prevention (CDC) was curated to …
This lesson plan from the Centers for Disease Control and Prevention (CDC) was curated to teach high school students, grades 9-10, to explore decision-making about the seasonal influenza (flu) vaccination. The lesson looks at financial decisions around vaccinations, based on a case study exploring the experiences of 282 children from cities around the United States. It looks at a wide range of factors including treatment for children with the flu and the cost of parents…
Decision Analysis | Clinical Care | Costing Methods | Infectious Diseases | Social Determinants | Economics/Finance | Health/Medicine | Science/Technology | North America | High School | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ArticlePublication 2015Population Health Model (POHEM): An Overview
This paper provides an overview of the rationale, methodology and applications of the Population Health …
This paper provides an overview of the rationale, methodology and applications of the Population Health Model (POHEM). POHEM is a health microsimulation model, developed at Statistics Canada in the early 1990s. The authors describe that POHEM draws together rich multivariate data from a wide range of sources to simulate the lifecycle of the Canadian population, specifically focusing on aspects of health. The model dynamically simulates individuals’ disease states, risk factors, and health determinants, in order…
Microsimulation | Clinical Care | Costing Methods | Evidence Synthesis | Mathematical Models | Calibration/Validation | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | North America -
ArticlePublication 2015Universal Public Finance of Tuberculosis Treatment in India: An Extended CEA
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India …
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India using extended cost-effectiveness analysis (ECEA). The authors evaluated the impact of UPF on health gains, financial consequences, and catastrophic health expenditures, and concluded that the health gains and insurance value of UPF would accrue mostly to the poor. However, reductions in out-of-pocket expenditures were found to be more uniformly distributed across income quintiles. A variant on the base case suggests…
Priority Setting/Ethics | Clinical Care | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Asia & Pacific -
ArticlePublication 2015Extended CEA: Surgical Access in Ethiopia
This chapter presents an extended cost-effectiveness analysis of strategies to improve access to surgical care …
This chapter presents an extended cost-effectiveness analysis of strategies to improve access to surgical care in rural Ethiopia, providing information on the health and financial risk protection benefits of policies. This chapter is from Essential Surgery, the first volume in the Disease Control Priorities, third edition (DCP3) series. The volume presents data on the surgical burden of disease, disability, congenital anomalies, and trauma, along with health impact and economic analyses of procedures, platforms, and packages…
Priority Setting/Ethics | Maternal/Reproductive Health | Costing Methods | Cost-Effectiveness Analysis | Child/Nutrition | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Preferences/Values | Mental Health | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology | North America -
ArticlePublication 2014Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness …
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness of alternate sequences of treatment strategies using second-generation antipsychotics (SGAs) for patients with schizophrenia. First-line treatments include one of the four SGAs: olanzapine (OLZ), risperidone (RSP), quetiapine (QTP), and ziprasidone (ZSD). Patients are able switch to another of these antipsychotics as second-line therapy, and only clozapine (CLZ) is allowed as third-line treatment. Model input parameters were obtained from the Clinical…
State-Transition | Mental Health | Cost-Effectiveness Analysis | Health/Medicine | North America